Dermatologists are practicing in an “era of good efficacy” of nonsteroidal topical therapies for psoriasis, and they can help patients access newer topical medications by working with pharmacies that ...

Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments, according to a study published in Annals ...

We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with a market capitalization of $75.2 billion and annual revenue of $14.2 billion ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

Regeneron Pharmaceuticals is taking another shot at US Food and Drug Administration (FDA) accelerated approval for odronextamab in relapsed/refractory follicular lymphoma (r/r FL), with the agency ...

Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing approval of linvoseltamab for certain adults ...

TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...

Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most ...

Regeneron Pharmaceuticals (NASDAQ:REGN), a leading biotechnology company with a market capitalization of $77 billion, finds itself at a critical juncture as it navigates challenges to its flagship ...